EGFR and non-small cell lung carcinoma: The epidermal growth factor receptor (EGFR) mutations, for instance, are common in patients with NSCLC [7], and are known to confer survival benefit and better clinical outcome when treated with EGFR tyrosine kinase inhibitors (TKIs) [8,9].